0000950170-23-006842.txt : 20230309 0000950170-23-006842.hdr.sgml : 20230309 20230309072555 ACCESSION NUMBER: 0000950170-23-006842 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230309 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230309 DATE AS OF CHANGE: 20230309 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vital Farms, Inc. CENTRAL INDEX KEY: 0001579733 STANDARD INDUSTRIAL CLASSIFICATION: FOOD & KINDRED PRODUCTS [2000] IRS NUMBER: 270496985 STATE OF INCORPORATION: DE FISCAL YEAR END: 1225 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39411 FILM NUMBER: 23718187 BUSINESS ADDRESS: STREET 1: 3601 SOUTH CONGRESS AVENUE STREET 2: SUITE C100 CITY: AUSTIN STATE: TX ZIP: 78704 BUSINESS PHONE: (877) 455-3063 MAIL ADDRESS: STREET 1: 3601 SOUTH CONGRESS AVENUE STREET 2: SUITE C100 CITY: AUSTIN STATE: TX ZIP: 78704 8-K 1 vitl-20230309.htm 8-K 8-K
0001579733false00015797332023-03-092023-03-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 9, 2023

 

Vital Farms, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39411

27-0496985

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

3601 South Congress Avenue

Suite C100

Austin, Texas

 

78704

(Address of Principal Executive Offices)

 

(Zip Code)

(877) 455-3036

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

VITL

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

Item 2.02 Results of Operations and Financial Condition.

On March 9, 2023, Vital Farms, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year ended December 25, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

 

 

Exhibit No.

 

Description

99.1

 

Press Release, dated March 9, 2023

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Vital Farms, Inc.

 

 

 

Dated: March 9, 2023

 

By:

 /s/ Bo Meissner

 

 

 

Bo Meissner

 

 

 

Chief Financial Officer

 

 


EX-99 2 vitl-ex99_1.htm EX-99.1 EX-99

Exhibit 99.1

 

Vital Farms Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Fourth Quarter Net Revenue a Record $110.1 million, up 42.2% versus Prior Year

Expects Net Revenue of More than $450 million in Fiscal Year 2023

AUSTIN, TX – March 9, 2023 Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its fourth quarter and fiscal year ended December 25, 2022.

Financial highlights for the fourth quarter and fiscal year ended December 25, 2022 include:

Fourth Quarter 2022 Net Revenue increase of 42.2% to $110.1 million
Fiscal Year 2022 Net Revenue increase of 38.8% to $362.1 million
Fiscal Year 2022 Net Income of $1.2 million
Fiscal Year 2022 Adjusted EBITDA of $16.2 million1

“2022 was another great year for Vital Farms’ financial results. We had a strong close to the year in Q4, achieving our highest net revenue in a single quarter driven by continued robust demand for our products. We also made significant gains in household penetration, growing the number of households who purchase Vital Farms products by over 45%, to 10.5 million,” said Russell Diez-Canseco, Vital Farms’ President and CEO.

Diez-Canseco continued, "Our continued success throughout this past year is a testament to the resilient stakeholder community of which we are a part. Specifically, I would like to recognize our crew members for their tireless efforts, and our farmers, whose passion for what they do and professionalism during all the change we experienced this past year is truly inspiring.”

1 Adjusted EBITDA is a non-GAAP financial measure defined in the section titled “Non-GAAP Financial Measures” below and is reconciled to net income, its closest comparable GAAP measure, at the end of this release.

For the 13 Weeks Ended December 25, 2022

Net revenue increased 42.2% to $110.1 million in the fourth quarter of 2022, compared to $77.4 million in the fourth quarter of 2021. Growth in net revenue in the fourth quarter of 2022 was driven by volume gains of 27%, primarily due to continued growth in egg-related sales, and pricing increases, as well as distribution gains at both new and existing retail customers.

Gross profit was $33.3 million, or 30.3% of net revenue, in the fourth quarter of 2022, compared to $19.8 million, or 25.6% of net revenue, in the prior year quarter. The change in gross profit was driven by higher sales. The change in gross margin was due to increased pricing across our entire portfolio despite facing some headwinds, including higher costs in both eggs and butter, elevated packaging costs, and increased farmer payments.

Income from operations in the fourth quarter of 2022 was $3.4 million, compared to a loss from operations of $4.2 million in the fourth quarter of 2021. The change in income from operations was primarily attributable to higher sales and gross profit, offset by increased employee-related expenses as we grew headcount to support our growth, as well as higher marketing costs.

Net income was $1.9 million in the fourth quarter of 2022, compared to a net loss of $3.6 million in the prior year quarter.

Net income per diluted share was $0.04 for the fourth quarter of 2022, compared to net loss per diluted share of $0.09 in the prior year quarter.

 


 

Adjusted EBITDA was $6.9 million, or 6.2% of net revenue, in the fourth quarter of 2022, compared to Adjusted EBITDA of $(2.0) million in the fourth quarter of 2021. The change in Adjusted EBITDA was primarily due to higher sales and improved gross profit performance in the face of a higher input cost environment, offset by increased employee-related expenses and higher marketing spend. Our Adjusted EBITDA excludes certain non-cash items. Adjusted EBITDA is a non-GAAP financial measure defined in the section titled “Non-GAAP Financial Measures” below and is reconciled to net income, its closest comparable GAAP measure, at the end of this release.

For the Fiscal Year Ended December 25, 2022

Net revenue increased 38.8% to $362.1 million in fiscal year 2022, compared to $260.9 million in fiscal year 2021. The change in net revenue in fiscal year 2022 was driven by volume growth of nearly 29%, due to continued growth in egg-related sales, distribution gains at both new and existing retail partners, and an increase in butter-related sales.

Gross profit was $109.4 million, or 30.2% of net revenue, in fiscal year 2022, compared to $82.9 million, or 31.8% of net revenue, in the prior year period. The change in gross profit was driven by higher sales. The change in gross margin was primarily driven by an increase in input costs across our shell egg and butter businesses, as well as higher packaging and transportation costs. Increased pricing on our portfolio partially offset the input cost headwinds.

Income from operations in fiscal year 2022 was $2.1 million, compared to income from operations of $52 thousand in fiscal year 2021. The change in net income from operations was primarily attributable to higher sales and gross profit, offset by increased employee-related expenses as we grew headcount to support our growth, as well as higher marketing costs.

Net income was $1.2 million in fiscal year 2022, compared to net income of $2.4 million in the prior year period.

Net income per diluted share was $0.03 in fiscal year 2022, compared to net income per diluted share of $0.06 in the prior year period.

Adjusted EBITDA was $16.2 million in fiscal year 2022, compared to Adjusted EBITDA of $8.0 million in fiscal year 2021. The change in Adjusted EBITDA was primarily due to higher sales and improved gross profit performance in the face of a higher input cost environment, partially offset by increased employee-related expenses to support growth across the business and higher marketing spend. Our Adjusted EBITDA excludes certain non-cash items as well as $2.3 million in costs related to the exit of our convenient breakfast product line in Q1 2022. Adjusted EBITDA is a non-GAAP financial measure defined in the section titled "Non-GAAP Financial Measures" below and is reconciled to net income, its closest comparable GAAP measure, at the end of this release.

Balance Sheet and Cash Flow Highlights

Cash and cash equivalents and investment securities were $78.7 million as of December 25, 2022, and we had no outstanding debt. Net cash used in operating activities was $8.1 million for the fiscal year ended December 25, 2022, compared to net cash provided by operating activities of $17.7 million for the fiscal year ended December 26, 2021.

Capital expenditures totaled $10.6 million in the fiscal year ended December 25, 2022, compared to $16.7 million in the prior year period.

 


 

Update on Fiscal Year 2023 Outlook

Bo Meissner, Vital Farms’ Chief Financial Officer, commented: “We are pleased with our financial performance and ongoing demand for our products. It has been a privilege serving as CFO of Vital Farms. As I prepare to step away from the company later this year, I would like to reiterate my confidence that Vital Farms is well positioned to further its progress toward its long-term top line objectives as well as its profitability goal of low double-digit Adjusted EBITDA Margin.”

For the full fiscal year 2023, management is providing guidance for net revenue of more than $450 million.
Management is also providing guidance for Adjusted EBITDA of more than $30 million for the full fiscal year 2023.
Finally, management expects fiscal year 2023 capital expenditures in the range of $25 to $30 million.

Vital Farms’ guidance continues to assume that there are no additional significant disruptions to the supply chain or its customers or consumers, including any issues from adverse macroeconomic factors. Vital Farms cannot provide a reconciliation between its forecasted Adjusted EBITDA and net income, or its forecasted Adjusted EBITDA Margin and net revenue, their respective most directly comparable GAAP measures, without unreasonable effort due to the unavailability of reliable estimates for income taxes, among other items. These items are not within our control and may vary greatly between periods and could significantly impact future financial results.

Conference Call and Webcast Details

Vital Farms will host a conference call and webcast at 8:30 a.m. ET today to discuss the results. To participate on the call and receive dial in information, please register here: Q4 2022 VITL Conference Call. Alternatively, participants may access the live webcast on the Vital Farms Investor Relations website at https://investors.vitalfarms.com under “Events.” The webcast will be archived in 30 days.

About Vital Farms

Vital Farms (Nasdaq: VITL), is a Certified B Corporation that offers a range of ethically produced foods nationwide. Started on a single farm in Austin, Texas in 2007, Vital Farms has become a national consumer brand that works with over 300 family farms and is the leading U.S. brand of pasture-raised eggs by retail dollar sales. Vital Farms' ethics are exemplified by its focus on the humane treatment of farm animals and sustainable farming practices. In addition, as a Delaware public benefit corporation, Vital Farms prioritizes the long-term benefits of each of its stakeholders, including farmers and suppliers, customers and consumers, communities and the environment, crew members, and stockholders. Vital Farms' products, including shell eggs, butter, hard-boiled eggs, ghee, and liquid whole eggs, are sold in over 22,000 stores nationwide. Vital Farms pasture raised eggs can also be found on menus at hundreds of foodservice operators across the country. For more information, please visit www.vitalfarms.com.

Forward-Looking Statements

This press release and the earnings call referencing this press release contain “forward-looking” statements, as that term is defined under the federal securities laws, including but not limited to statements regarding Vital Farms’ market opportunity, anticipated growth, ability to successfully enter into new product categories, and future financial performance, including management’s outlook for fiscal year 2023 and management's long-term outlook. These forward-looking statements are based on Vital Farms’ current assumptions, expectations, and beliefs and are subject to substantial risks, uncertainties, assumptions, and changes in circumstances that may cause Vital Farms’ actual results, performance, or achievements to differ materially from those expressed or implied in any forward-looking statement.

 


 

The risks and uncertainties referred to above include, but are not limited to: Vital Farms’ expectations regarding its revenue, expenses, and other operating results; Vital Farms’ ability to acquire new customers, to successfully retain existing customers, and to attract and retain its farmers, suppliers, distributors, and co-manufacturers; Vital Farms’ ability to sustain or increase its profitability; Vital Farms’ ability to procure sufficient high-quality eggs, cream, and other raw materials; Vital Farms' ability to successfully enter into new product categories; real or perceived quality with Vital Farms’ products or other issues that adversely affect Vital Farms’ brand and reputation; changes in the tastes and preferences of consumers; the financial condition of, and Vital Farms’ relationships with, its farmers, suppliers, co-manufacturers, distributors, retailers, and foodservice customers, as well as the health of the foodservice industry generally; the impact of agricultural risks, including diseases such as avian influenza; the ability of Vital Farms, its farmers, suppliers, and its co-manufacturers to comply with food safety, environmental or other laws or regulations; the effects of a public health pandemic or contagious disease on Vital Farms' supply chain, the demand for its products, and on overall economic conditions and consumer confidence and spending levels; future investments in its business, anticipated capital expenditures and estimates regarding capital requirements; anticipated changes in Vital Farms’ product offerings and Vital Farms’ ability to innovate to offer successful new products; the costs and success of marketing efforts; Vital Farms’ ability to effectively manage its growth and to compete effectively with existing competitors and new market entrants; the impact of adverse economic conditions, including as a result of the war between Ukraine and Russia, increased interest rates and inflation; the potential negative impact of Vital Farms’ focus on a specific public benefit purpose and producing a positive effect for society on its financial performance; seasonality; and the growth rates of the markets in which Vital Farms competes.

These risks and uncertainties are more fully described in Vital Farms’ filings with the Securities and Exchange Commission (SEC), including in the sections entitled “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 25, 2022, which Vital Farms anticipates filing on March 9, 2023, and its Quarterly Report on Form 10-Q for the fiscal quarter ended September 25, 2022, and other filings and reports that Vital Farms may file from time to time with the SEC. Moreover, Vital Farms operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for management to predict all risks, nor can Vital Farms assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Vital Farms may make. In light of these risks, uncertainties, and assumptions, Vital Farms cannot guarantee future results, levels of activity, performance, achievements, or events and circumstances reflected in the forward-looking statements will occur. Forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. Vital Farms disclaims any obligation to update forward-looking statements except as required by law.

Media:

Rob Discher

rob.discher@vitalfarms.com

Investors:

Matt Siler

Matt.Siler@vitalfarms.com

 

 


 

VITAL FARMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except share amounts)

 

 

 

13-Weeks Ended

 

 

52-Weeks Ended

 

 

 

December 25,
2022

 

 

December 26,
2021

 

 

December 25,
2022

 

 

December 26,
2021

 

Net revenue

 

$

110,081

 

 

$

77,405

 

 

$

362,050

 

 

$

260,901

 

Cost of goods sold

 

 

76,768

 

 

 

57,608

 

 

 

252,606

 

 

 

178,002

 

Gross profit

 

 

33,313

 

 

 

19,797

 

 

 

109,444

 

 

 

82,899

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

22,043

 

 

 

15,815

 

 

 

77,236

 

 

 

57,868

 

Shipping and distribution

 

 

7,825

 

 

 

8,224

 

 

 

30,104

 

 

 

24,979

 

Total operating expenses

 

 

29,868

 

 

 

24,039

 

 

 

107,340

 

 

 

82,847

 

Income (loss) from operations

 

 

3,445

 

 

 

(4,242

)

 

 

2,104

 

 

 

52

 

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(87

)

 

 

(10

)

 

 

(114

)

 

 

(52

)

Interest income

 

 

340

 

 

 

101

 

 

 

992

 

 

 

381

 

Other income (expense), net

 

 

 

 

 

(46

)

 

 

(151

)

 

 

(27

)

Total other income (expense), net

 

 

253

 

 

 

45

 

 

 

727

 

 

 

302

 

Net income (loss) before income taxes

 

 

3,698

 

 

 

(4,197

)

 

 

2,831

 

 

 

354

 

Income tax provision (benefit)

 

 

1,833

 

 

 

(543

)

 

 

1,601

 

 

 

(2,028

)

Net income (loss)

 

 

1,865

 

 

 

(3,654

)

 

 

1,230

 

 

 

2,382

 

Less: Net loss attributable to
   noncontrolling interests

 

 

 

 

 

(6

)

 

 

(21

)

 

 

(47

)

Net income (loss) attributable to Vital Farms, Inc.
   common stockholders

 

$

1,865

 

 

$

(3,648

)

 

$

1,251

 

 

$

2,429

 

Net income (loss) per share attributable to Vital
   Farms, Inc. stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Basic:

 

$

0.05

 

 

$

(0.09

)

 

$

0.03

 

 

$

0.06

 

Diluted:

 

$

0.04

 

 

$

(0.09

)

 

$

0.03

 

 

$

0.06

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic:

 

 

40,738,158

 

 

 

40,379,765

 

 

 

40,648,592

 

 

 

40,027,278

 

Diluted:

 

 

43,391,224

 

 

 

40,379,765

 

 

 

43,469,586

 

 

 

43,321,733

 

 

 


 

VITAL FARMS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share amounts)

 

 

 

December 25,
2022

 

 

December 26,
2021

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

12,914

 

 

$

30,966

 

Investment securities, available-for-sale

 

 

65,814

 

 

 

68,621

 

Accounts receivable, net

 

 

40,227

 

 

 

26,938

 

Inventories

 

 

26,849

 

 

 

10,945

 

Prepaid expenses and other current assets

 

 

3,810

 

 

 

3,817

 

Total current assets

 

 

149,614

 

 

 

141,287

 

Property, plant and equipment, net

 

 

59,155

 

 

 

44,608

 

Operating lease right-of-use assets

 

 

1,895

 

 

 

 

Goodwill

 

 

3,858

 

 

 

3,858

 

Other assets

 

 

144

 

 

 

189

 

Total assets

 

$

214,666

 

 

$

189,942

 

Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

25,972

 

 

$

22,520

 

Accrued liabilities

 

 

18,477

 

 

 

15,143

 

Operating lease liabilities, current

 

 

1,208

 

 

 

 

Finance lease liabilities, current

 

 

1,570

 

 

 

327

 

Income taxes payable

 

 

425

 

 

 

 

Total current liabilities

 

 

47,652

 

 

 

37,990

 

Operating lease liabilities, non-current

 

 

892

 

 

 

 

Finance lease liabilities, non-current

 

 

7,023

 

 

 

 

Other liabilities

 

 

767

 

 

 

192

 

Total liabilities

 

$

56,334

 

 

$

38,182

 

Commitments and contingencies (Note 17)

 

 

 

 

 

 

Redeemable noncontrolling interest

 

 

 

 

 

175

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.0001 par value per share, 310,000,000 shares authorized as of December 25, 2022 and December 26, 2021; 40,746,990 and 40,493,969 shares issued and outstanding as of December 25, 2022 and December 26, 2021, respectively

 

 

4

 

 

 

5

 

Additional paid-in capital

 

 

155,716

 

 

 

149,000

 

Retained earnings

 

 

4,159

 

 

 

2,746

 

Accumulated other comprehensive loss

 

 

(1,547

)

 

 

(281

)

Total stockholders’ equity attributable to Vital Farms, Inc. stockholders

 

 

158,332

 

 

 

151,470

 

Noncontrolling interests

 

 

 

 

 

115

 

Total stockholders’ equity

 

$

158,332

 

 

$

151,585

 

Total liabilities, redeemable noncontrolling interest, and stockholders’ equity

 

$

214,666

 

 

$

189,942

 

 

 


 

VITAL FARMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

 

 

 

52-Weeks Ended

 

 

 

December 25,
2022

 

 

December 26,
2021

 

Cash flows from operating activities:

 

 

 

 

 

 

Net (loss) income

 

$

1,230

 

 

$

2,382

 

Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

5,441

 

 

 

3,540

 

Amortization of right-of-use assets

 

 

1,840

 

 

 

 

Amortization of available-for-sale debt securities

 

 

711

 

 

 

1,301

 

Stock-based compensation expense

 

 

6,040

 

 

 

4,440

 

Bad debt expense

 

 

430

 

 

 

73

 

(Decrease) increase in inventory provision

 

 

(330

)

 

 

224

 

Deferred taxes

 

 

632

 

 

 

(2,536

)

Other

 

 

84

 

 

 

44

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(13,718

)

 

 

(6,078

)

Inventories

 

 

(15,574

)

 

 

1,733

 

Income taxes receivable

 

 

199

 

 

 

1,354

 

Prepaid expenses and other current assets

 

 

(271

)

 

 

426

 

Deposits and other assets

 

 

45

 

 

 

(46

)

Income taxes payable

 

 

425

 

 

 

 

Accounts payable

 

 

2,352

 

 

 

6,796

 

Accrued liabilities

 

 

3,843

 

 

 

4,029

 

Operating lease liabilities

 

 

(1,477

)

 

 

 

Net cash (used in) provided by operating activities

 

$

(8,098

)

 

$

17,682

 

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property, plant and equipment

 

 

(10,468

)

 

 

(16,711

)

Purchases of leasehold improvements

 

 

(89

)

 

 

 

Purchases of available-for-sale debt securities

 

 

(33,817

)

 

 

(51,688

)

Sales of available-for-sale debt securities

 

 

 

 

 

1,436

 

Maturities and call redemptions of available-for-sale debt securities

 

 

34,345

 

 

 

48,523

 

Proceeds from the sale of property, plant and equipment

 

 

100

 

 

 

 

Dissolution of noncontrolling interest

 

 

(108

)

 

 

 

     Net cash used in investing activities

 

$

(10,037

)

 

$

(18,440

)

Cash flows from financing activities:

 

 

 

 

 

 

Payment of contingent consideration

 

 

(38

)

 

 

(152

)

Principal payments under finance lease obligations

 

 

(554

)

 

 

(471

)

Proceeds from exercise of stock options

 

 

675

 

 

 

2,803

 

Net cash provided by financing activities

 

$

83

 

 

$

2,180

 

Net decrease in cash and cash equivalents

 

 

(18,052

)

 

 

1,422

 

Cash and cash equivalents at beginning of the period

 

 

30,966

 

 

 

29,544

 

Cash and cash equivalents at end of the period

 

$

12,914

 

 

$

30,966

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

Cash paid for interest

 

$

114

 

 

$

43

 

Cash paid for income taxes

 

$

99

 

 

$

102

 

Supplemental disclosure of non-cash investing and financing
   activities:

 

 

 

 

 

 

Purchases of property, plant and equipment included in accounts payable and accrued liabilities

 

$

1,143

 

 

$

1,493

 

 

 


 

Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that Adjusted EBITDA and Adjusted EBITDA Margin, non-GAAP financial measures, provide investors with additional useful information in evaluating our performance.

Adjusted EBITDA and Adjusted EBITDA Margin are financial measures that are not required by or presented in accordance with GAAP. We believe that Adjusted EBITDA and Adjusted EBITDA Margin, when taken together with our financial results presented in accordance with GAAP, provide meaningful supplemental information regarding our operating performance and facilitate internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA and Adjusted EBITDA Margin are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation and evaluating our operating performance, as well as for internal planning and forecasting purposes.

We calculate Adjusted EBITDA as net income, adjusted to exclude: (1) depreciation and amortization; (2) (benefit) or provision for income taxes as applicable; (3) stock-based compensation expense; (4) interest expense; (5) change in fair value of contingent consideration; (6) interest income; (7) the costs related to the discontinuation of our convenient breakfast product line; and (8) the costs related to the dissolution of the Ovabrite, Inc. variable interest entity. We believe the costs directly related to the convenient breakfast exit and dissolution of Ovabrite, Inc. should be excluded as they are unlikely to recur. We calculate Adjusted EBITDA Margin as Adjusted EBITDA divided by Net Revenue.

Adjusted EBITDA and Adjusted EBITDA margin are presented for supplemental informational purposes only, have limitations as analytical tools and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA and Adjusted EBITDA Margin include that (1) they do not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA and Adjusted EBITDA Margin do not reflect these capital expenditures; (3) they do not consider the impact of stock-based compensation expense; (4) they do not include costs related to the discontinuation of our convenient breakfast product line; (5) they do not reflect the dissolution of the Ovabrite, Inc. variable interest entity; (6) they do not reflect other non-operating expenses, including interest expense; (7) they do not consider the impact of any contingent consideration liability valuation adjustments and (8) they do not reflect tax payments that may represent a reduction in cash available to us. In addition, our use of Adjusted EBITDA and Adjusted EBITDA Margin may not be comparable to similarly titled measures of other companies because they may not calculate Adjusted EBITDA in the same manner, limiting the usefulness as comparative measures. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA and Adjusted EBITDA Margin alongside other financial measures, including our net income and other results stated in accordance with GAAP.

The following table presents a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable financial measure stated in accordance with GAAP, for the 13-week and 52-week periods presented. A reconciliation of Adjusted EBITDA Margin to net revenue, its most directly comparable GAAP measure, is not available on a forward-looking basis without unreasonable effort due to the unavailability of reliable estimates for income taxes, among other items.

 

 


 

VITAL FARMS, INC.

ADJUSTED EBITDA RECONCILIATION

(Amounts in thousands)

 

 

 

13-Weeks Ended

 

 

52-Weeks Ended

 

 

 

December 25,
2022

 

 

December 26,
2021

 

 

December 25,
2022

 

 

December 26,
2021

 

 

 

(in thousands)

 

 

(in thousands)

 

Net income (loss)

 

$

1,865

 

 

$

(3,654

)

 

$

1,230

 

 

$

2,382

 

Depreciation and amortization(1)

 

 

1,870

 

 

 

1,014

 

 

 

5,761

 

 

 

3,540

 

Stock-based compensation expense

 

 

1,542

 

 

 

1,243

 

 

 

6,040

 

 

 

4,440

 

Costs related to our exit of the convenient breakfast product line

 

 

 

 

 

 

 

 

2,341

 

 

 

 

Dissolution of Ovabrite, Inc.

 

 

 

 

 

 

 

 

122

 

 

 

 

Income tax provision (benefit)

 

 

1,833

 

 

 

(544

)

 

 

1,601

 

 

 

(2,028

)

Interest expense

 

 

87

 

 

 

10

 

 

 

114

 

 

 

52

 

Change in fair value of contingent consideration(2)

 

 

 

 

 

10

 

 

 

19

 

 

 

44

 

Interest income

 

 

(340

)

 

 

(101

)

 

 

(992

)

 

 

(381

)

Adjusted EBITDA

 

$

6,857

 

 

$

(2,022

)

 

$

16,236

 

 

$

8,049

 

 

(1)
Amount also includes finance lease amortization.
(2)
Amount reflects the change in fair value of a contingent consideration liability in connection with our 2014 acquisition of certain assets of Heartland Eggs.

 


EX-101.SCH 3 vitl-20230309.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vitl-20230309_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address City Or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Entity Incorporation State Country Code Entity Incorporation, State or Country Code City Area Code City Area Code Document Period End Date Document Period End Date Entity Address Postal Zip Code Entity Address, Postal Zip Code Entity File Number Entity File Number Entity Address Address Line1 Entity Address, Address Line One Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Pre Commencement Tender Offer Pre-commencement Tender Offer Security12b Title Security 12b Title Entity Address State Or Province Entity Address, State or Province Document Type Document Type Written Communications Written Communications Security Exchange Name Security Exchange Name Entity Address Address Line2 Entity Address, Address Line Two Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Trading Symbol Trading Symbol EX-101.PRE 5 vitl-20230309_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Mar. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 09, 2023
Entity Registrant Name Vital Farms, Inc.
Entity Central Index Key 0001579733
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-39411
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 27-0496985
Entity Address, Address Line One 3601 South Congress Avenue
Entity Address, Address Line Two Suite C100
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78704
City Area Code 877
Local Phone Number 455-3036
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol VITL
Security Exchange Name NASDAQ
XML 7 vitl-20230309_htm.xml IDEA: XBRL DOCUMENT 0001579733 2023-03-09 2023-03-09 0001579733 false 8-K 2023-03-09 Vital Farms, Inc. DE 001-39411 27-0496985 3601 South Congress Avenue Suite C100 Austin TX 78704 877 455-3036 false false false false Common Stock VITL NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports vitl-20230309.htm vitl-20230309.xsd vitl-20230309_lab.xml vitl-20230309_pre.xml vitl-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vitl-20230309.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "vitl-20230309.htm" ] }, "labelLink": { "local": [ "vitl-20230309_lab.xml" ] }, "presentationLink": { "local": [ "vitl-20230309_pre.xml" ] }, "schema": { "local": [ "vitl-20230309.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vitl", "nsuri": "http://vitalfarms.com/20230309", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vitl-20230309.htm", "contextRef": "C_21565a86-8890-4ebf-bc26-9bad17f683be", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vitl-20230309.htm", "contextRef": "C_21565a86-8890-4ebf-bc26-9bad17f683be", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vitalfarms.com/20230309/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-006842-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-006842-xbrl.zip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�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end